Anti-ActRII antibodies and their applications
By designing anti-ActRII antibodies or their antigen-binding fragments with specific amino acid sequences, the problem of insufficient antibody selection has been solved, enabling precise regulation of muscle growth and fat metabolism and providing more clinical treatment options.
Patent Information
- Application Number
- CN202610094600.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-01-23
- Publication Date
- 2026-11-17
AI Technical Summary
There is still a need for more options for existing anti-ActRII antibodies in clinical applications to meet the treatment needs of different diseases.
An anti-ActRII antibody or its antigen-binding fragment containing a specific amino acid sequence is provided, which improves the binding affinity and selectivity to ActRII through a specific combination of HCDR and LCDR.
It enhances the therapeutic effect of anti-ActRII antibodies, enabling more precise regulation of muscle growth and fat metabolism, and providing more clinical treatment options.
Smart Images

Figure CN123106899A_ABST
Abstract
Description
Technical Field
[0001] This disclosure belongs to the field of biomedical technology, specifically relating to anti-ActRII antibodies and their applications. Background Technology
[0002] Activin type II receptors (ActRIIs), as core mediators of the transforming growth factor β (TGF-β) superfamily signaling pathway, play a crucial role in cellular signaling networks. This family includes two structurally homologous subtypes—activin type II receptor A (ActRIIA / ACVR2A) and activin type II receptor B (ActRIIB / ACVR2B). Both consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular kinase domain. Through highly conserved domains, they specifically bind to ligands, initiating downstream signaling cascades.
[0003] ActRII signaling activation depends on precise binding to specific ligands, whose ligand spectrum is known to include multiple family members such as activins (e.g., Activin A) and growth differentiation factors (e.g., GDF8 / myostatin, GDF11). After binding to the ligand, ActRII recruits and phosphorylates TGF-β superfamily type I receptors, thereby activating downstream Smad2 / 3 signaling molecules. Phosphorylated Smad2 / 3 forms a heterologous complex with Smad4, which translocates into the cell nucleus to regulate the transcription of target genes, ultimately participating in several key physiological processes such as muscle growth regulation, lipid metabolism homeostasis, and immune microenvironment homeostasis.
[0004] In muscle tissue, activation of the ActRII signaling pathway has a clear negative regulatory effect. Studies have confirmed that after the ligand GDF8 binds to ActRIIB, it can inhibit the expression of myocyte-specific transcription factors (such as MyoD and MyoG) through the Smad signaling pathway, hindering myoblast proliferation and differentiation, while promoting the activation of myofibril degradation-related genes (such as Atrogin-1 and MuRF1), ultimately leading to muscle atrophy. This mechanism plays a central role in muscle loss in diseases such as muscular dystrophy and cachexia.
[0005] In adipose tissue, the ActRII signaling pathway promotes adipogenesis. After Activin A binds to ActRII, it can upregulate the expression of key adipogenesis factors such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C / EBPα) through Smad3 signaling, accelerating the transformation of preadipocytes into mature adipocytes. At the same time, it promotes the activity of lipid synthesis-related enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), enhancing the lipid storage capacity of adipose tissue. Abnormal activation of ActRII is closely related to the occurrence of obesity and metabolic syndrome.
[0006] Anti-ActRII antibodies are already under development in clinical practice, but new anti-ActRII antibodies still need to be developed to provide more clinical treatment options. Invention Summary This disclosure provides anti-ActRII antibodies and their antigen-binding fragments, as well as related nucleic acids, vectors, cells, pharmaceutical compositions, preparation methods, and uses encoding the provided antibodies and their antigen-binding fragments.
[0007] In one aspect, this disclosure provides an anti-ActRII antibody or its antigen-binding fragment, comprising: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 2, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 8, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 14, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 18, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24. The amino acid sequence of SEQ ID NO: 2 is VIX1YDGRX2KX3YADSVKG, where X1 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; X2 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and X3 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. The amino acid sequence of SEQ ID NO: 8 is EGX7ARYX8GMDV, where X7 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V, and X8 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. The amino acid sequence of SEQ ID NO: 14 is RASQSINSX. 11 LN, X 11=A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, The amino acid sequence of SEQ ID NO: 18 is X 13 AX 14 NLX 15 S, X 13 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 14 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 15 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0008] In one aspect, this disclosure provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: (1) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (2) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (3) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (4) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (5) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (6) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (7) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (8) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (9) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (10) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (11) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (12) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (13) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (14) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (15) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (16) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (17) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (18) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (19) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (20) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (21) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (22) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (23) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (24) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (25) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (26) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (27) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (28) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (29) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (30) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (31) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (32) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (33) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (34) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (35) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (36) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (37) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (38) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (39) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (40) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (41) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (42) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (43) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (44) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; or (45) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0009] In one aspect, this disclosure provides an anti-ActRII antibody or its antigen-binding fragment, comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 25, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 39, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG. The amino acid sequence of SEQ ID NO: 25 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 19 YDGRX 20 KX 21 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 22 ARYX 23 GMDVWGQGTTVTVSS, X 19 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 20 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 21 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 22=A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 23 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, The amino acid sequence of SEQ ID NO: 39 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 29 LNWYQQKPGKDPKLLIYX 30 AX 31 NLX 32 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 29 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 30 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 31 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 32 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0010] In one aspect, this disclosure provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (16) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (17) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (18) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (19) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (20) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (21) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (22) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (23) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (24) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (25) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (26) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (27) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (28) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (29) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (30) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (31) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (32) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (33) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (34) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (35) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (36) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (37) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (38) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (39) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46; (40) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (41) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (42) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (43) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46; (44) The amino acid sequences of HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; or (45) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; The CDR mentioned therein is defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0011] In one aspect, this disclosure provides isolated nucleic acids comprising nucleotide sequences encoding the anti-ActRII antibody or its antigen-binding fragment as described in this disclosure.
[0012] In one respect, this disclosure provides a carrier containing the nucleic acid described herein.
[0013] In one respect, this disclosure provides a host cell containing the nucleic acid or the vector described herein.
[0014] In one aspect, this disclosure provides a fusion protein comprising the anti-ActRII antibody of this disclosure or an antigen-binding fragment thereof.
[0015] In one aspect, this disclosure provides antibody-drug conjugates comprising the anti-ActRII antibody of this disclosure or its antigen-binding fragment.
[0016] In one aspect, this disclosure provides an anti-ActRII chimeric antigen receptor comprising the anti-ActRII antibody of this disclosure or its antigen-binding fragment.
[0017] In one aspect, this disclosure provides engineered immune effector cells that contain the chimeric antigen receptor of this disclosure.
[0018] On the other hand, this disclosure provides a method for preparing the anti-ActRII antibody or its antigen-binding fragment as described herein, comprising culturing the host cells to express the ActRII antibody or its antigen-binding fragment, and isolating and purifying the anti-ActRII antibody or its antigen-binding fragment in the system.
[0019] On the other hand, this disclosure provides pharmaceutical compositions comprising the anti-ActRII antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate or the engineered immune effector cells, and pharmaceutically acceptable excipients.
[0020] On the other hand, this disclosure provides the use of the anti-ActRII antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition in the preparation of a medicament for treating diseases related to ActRII expression or ActRII signaling.
[0021] On the other hand, this disclosure provides a method for treating diseases associated with ActRII expression or ActRII signaling, comprising administering to a subject the anti-ActRII antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition.
[0022] The anti-ActRII antibody or its antigen-binding fragment disclosed herein demonstrates good efficacy and safety in treating diseases related to ActRII expression or ActRII signaling. Attached Figure Description
[0023] Figure 1A-1H The binding activity of the anti-ActRII antibody protein to human ActRIIA or ActRIIB was demonstrated. Figure 2A-2D The cell-based binding activity of the anti-ActRII antibody to human ActRIIA or ActRIIB was demonstrated. Figures 3A-3E This demonstrates the protein-based blocking activity of the anti-ActRII antibody against the binding of ActRII to Activin A; Figures 4A-4E This demonstrates the protein-based blocking activity of the anti-ActRII antibody against the binding of ActRIIB to Activin A; Figure 5A-5G The activity of anti-ActRII antibodies in blocking the binding of ActRII to Activin A, GDF8, or Activin B on a cell-based basis was demonstrated. Figure 6A-6M The activity of the anti-ActRII antibody in blocking the binding of ActRIIB to Activin A on a cell-based basis was demonstrated. Figures 7A-7D The activity of the anti-ActRII antibody in blocking the binding of ActRIIB to GDF8 on a cell-based basis was demonstrated. Figure 8 The activity of the anti-ActRII antibody in blocking the binding of ActRIIB to Activin B on a cell-based basis was demonstrated. Figures 9A-9D The activity of the anti-ActRII antibody in blocking the binding of ActRIIA and ActRIIB to Activin A on a cell-based basis was demonstrated. Figures 10A-10C The activity of the anti-ActRII antibody in blocking the binding of ActRIIA and ActRIIB to GDF8 on a cell-based basis was demonstrated. Figure 11 The activity of the anti-ActRII antibody in blocking the binding of ActRIIA and ActRIIB to Activin B on a cell-based basis was demonstrated. Figure 12A-12B The effect of anti-ActRII antibody on body weight changes in DIO mice was shown. Figures 13A-13D The effects of anti-ActRII antibody on body composition in DIO model mice were shown. Figures 14A-14D The effects of anti-ActRII antibody on the absolute and relative weight of muscle tissue in DIO model mice were shown. Figure 15A-15F The effects of anti-ActRII antibody on the absolute and relative weight of adipose tissue in DIO model mice were shown. Figures 16A-16E The effects of anti-ActRII antibody on serum biochemical parameters in DIO model mice were shown. Figures 17A-17B The pharmacokinetic characteristics of the anti-ActRII antibody in cynomolgus monkeys are shown. Invention Details Definitions and Explanations Unless otherwise stated, the following terms as used in this disclosure have the following meanings. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0025] "Activin type II receptor" (also known as "Activin Receptor Type II", "ActRII" or "ACVR2", which are used interchangeably in this disclosure) is a type II transmembrane receptor protein belonging to the transforming growth factor-β (TGF-β) superfamily, including two subtypes: "Activin type II receptor A" (also known as "Activin Receptor Type IIA", "ActRIIA" or "ACVR2A", which are used interchangeably in this disclosure) and "Activin type II receptor B" (also known as "Activin Receptor Type IIB", "ActRIIB" or "ACVR2B", which are used interchangeably in this disclosure). In this disclosure, “ActRIIA” refers to a naturally occurring ActRIIA polypeptide (e.g., Uniprot: P27037), its variants (including but not limited to point mutants, truncated forms, and fusion proteins), or a biologically active fragment having at least 80% sequence homology with its ligand-binding domain; “ActRIIB” refers to a naturally occurring ActRIIB polypeptide (e.g., Uniprot: Q13705), its variants (including but not limited to point mutants, truncated forms, and fusion proteins), or a biologically active fragment having at least 80% sequence homology with its ligand-binding domain.
[0026] The term "antibody" is used in the broadest sense to encompass a variety of natural and artificial antibodies, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies), and various antibody structures of single-chain antibodies, as long as they exhibit the desired antigen-binding activity.
[0027] The term “antigen-binding fragment” refers to one or more fragments of an antibody that retain the function of specifically binding to an antigen. Examples covered by the term “antigen-binding fragment” include: (i) Fab fragments: monovalent fragments consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments containing two Fab fragments connected by a disulfide bridge in the hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains of an antibody single arm; (v) dAb fragments consisting of VH domains (see Ward et al., Nature. 341:544-546 (1989)); (vi) separated complementarity-determining regions (CDRs); (vii) nanobodies; and single-chain Fv (scFv).
[0028] The term "variable domain" or "variable region" refers to a domain of an antibody involved in the binding of the antibody to an antigen. For example, natural four-chain antibodies (e.g., derived from humans, mice, etc.) have a heavy chain variable domain (also called a heavy chain variable domain, VH, or VH domain) and a light chain variable domain (also called a light chain variable domain, VL, or VL domain). In most cases, each variable domain of a natural antibody essentially consists of four "frame regions (FRs)" and three "complementarity-determining regions (CDRs)." The four frame regions are referred to as frame region 1 (or FR1), frame region 2 (or FR2), frame region 3 (or FR3), and frame region 4 (or FR4), respectively; these frame regions are separated by three complementarity-determining regions, referred to in the art and hereinafter as complementarity-determining regions 1 (or CDR1), 2 (or CDR2), and 3 (or CDR3), respectively. Therefore, the general structure of a variable domain can be represented as: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Variable domains endow antibodies with antigen specificity because they have antigen-binding sites.
[0029] The term "complementarity-determining region" (CDR) is also known as the "hypervariant region" (HVR). Natural four-chain antibodies typically contain six CDRs: three in the heavy chain variable region, namely heavy chain CDR1 (HCDR1), heavy chain CDR2 (HCDR2), and heavy chain CDR3 (HCDR3); and three in the light chain variable region, namely light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3).
[0030] Currently, there are many methods for defining CDRs. The Kabat definition, based on sequence variability, is the most commonly used (Elvin A. Kabat, et al, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)); while the Chothia definition is based on the location of structural loops (Cyrus Chothia, et al, Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol. 196:901-917 (1987)). The AbM definition is a compromise between the Kabat and Chothia definitions and is used by the AbM antibody modeling software from Oxford Molecular. The "contact" definition of CDRs is based on the analysis of available complex crystal structures. Other definitions include IMGT and CCG. However, it should be noted that the boundaries of the CDRs (Continuous Derivatives) of the same antibody variable region obtained by different methods may differ; that is, the CDR sequences of the same antibody variable region defined by different methods may be different. Therefore, when referring to antibodies defined by a specific CDR sequence, the scope of the antibody also includes antibodies defined by CDR sequences of other arbitrary definitions (e.g., one or more combinations of definitions such as Kabat, IMGT, Chothia, Contact, AbM, CCG, etc.).
[0031] The term “treatment” means administering the compounds (e.g., antibodies) or pharmaceutical compositions described in this disclosure to prevent, improve, or eliminate a disease or one or more symptoms associated with said disease, including but not limited to: (i) preventing the occurrence of a disease or disease state in mammals, particularly when such mammals are susceptible to the disease state but have not yet been diagnosed with it; (ii) suppressing a disease or disease state, i.e., halting its development; (iii) alleviating a disease or disease state, even if the disease or disease state subsides; and (iv) reducing any direct or indirect pathological consequences of the disease or disease state.
[0032] The term “therapeutic effective amount” means (i) the amount of the disclosed compound used to treat or prevent a particular disease, condition, or disorder; (ii) to reduce, improve, or eliminate one or more symptoms of a particular disease, condition, or disorder; or (iii) to prevent or delay the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of the disclosed anti-ActRII antibody or its antigen-binding fragment, fusion protein, antibody-drug conjugate, engineered immune effector cell, or pharmaceutical composition constituting a “therapeutic effective amount” may vary depending on factors such as the compound or pharmaceutical composition and its ability to elicit a desired response in an individual, the disease state and its severity, the route of administration, and the age, sex, and weight of the mammal to be treated.
[0033] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0034] The term "excipient" refers to any component other than the active ingredient (e.g., the antibody of this disclosure). The selection of excipients will depend to a great extent on factors such as the specific method of administration, the efficacy of the excipient in terms of solubility and stability, and the nature of the dosage form.
[0035] The term "isolated" refers to a target compound that has been isolated from its natural environment, such as an antibody or its antigen-binding fragment or nucleic acid.
[0036] Term "X" n "Xaa" is equivalent to "Xaa" and refers to unspecified amino acids, the scope of which is specified by subsequent definitions in the relevant description.
[0037] As used in this article, the term "EC" 50 "IC50" refers to the antibody concentration at which the induced response is 50% of the maximum response, i.e., half the distance between the maximum response and the baseline. 50 "Hypermodity concentration" (MCC) refers to the concentration of antibody required to achieve 50% inhibition of a biological process. 50 or IC 50 It can be measured by ELISA or FACS analysis or any other method known in the art.
[0038] “K D "Refers to the equilibrium dissociation constant, which is the self-dissociation rate constant (k)" d ) relative to the binding rate constant (k a(i.e., k) d / k a The ratio of K to α is expressed as molar concentration (M). The K of the antibody D The value can be determined using methods well-established in the art. The K value used for antibody determination... D The preferred method is to use surface plasmon resonance (SPR) technology, preferably using a biosensor system such as the Biacore surface plasmon resonance system for analysis.
[0039] The term "identity," also known as consistency, refers to the percentage of amino acid residues in the sequence to be aligned that are identical to those in the specific amino acid sequence shown herein, after aligning the sequence to be aligned with it and, if necessary, introducing vacancies to achieve the maximum percentage of sequence identity, and without considering any conservative substitutions as part of the sequence identity. Amino acid sequence alignment for identity can be performed using various methods within the art, such as BLAST, BLAST-2, etc. Those skilled in the art can determine the appropriate parameters for the aligned sequences, including any algorithm required to achieve maximum alignment across the full length of the compared sequences.
[0040] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, including non-human primates, sheep, goats, dogs, cats, horses, cattle, chickens, amphibians, reptiles, etc. Preferably, the subject according to this disclosure is a human. Unless otherwise stated, the terms "patient" or "subject" may be used interchangeably.
[0041] As used herein, “about” means within the acceptable range of error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” may, in accordance with art practice, mean within one or more standard deviations. Alternatively, “about” may mean a range of up to ±5%, such as fluctuations within ±2%, ±1%, or ±0.5% of a given specific numerical range. When a particular value is given in the scope of this disclosure, unless otherwise stated, “about” shall be understood to mean within the acceptable range of error for that particular value. In this document, unless otherwise stated, the values of step parameters or conditions are implicitly modified by “about”.
[0042] The terms “comprise,” “containing,” and “comprising” and their equivalents (e.g., contain, contains, containing, include, includes, and including) shall be understood as “including but not limited to,” meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be covered.
[0043] In this document, unless the context clearly indicates otherwise, singular terms encompass plural referents, and vice versa.
[0044] Anti-ActRII antibody or its antigen-binding fragment This disclosure provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 2, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 8, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 14, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 18, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0045] In some embodiments, the amino acid sequence of SEQ ID NO: 2 is VIX1YDGRX2KX3YADSVKG, where X1 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X2 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, and X3 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0046] In some embodiments, the amino acid sequence of SEQ ID NO: 8 is EGX7ARYX8GMDV, where X7 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, and X8 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0047] In some embodiments, the amino acid sequence of SEQ ID NO: 14 is RASQSINSX. 11 LN, X 11 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0048] In some embodiments, the amino acid sequence of SEQ ID NO: 18 is X. 13 AX 14 NLX 15 S, X 13 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 14 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 15 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0049] In some embodiments, the amino acid sequence of SEQ ID NO: 2 is VIX1YDGRX2KX3YADSVKG, where X1 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X2 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, and X3 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; The amino acid sequence of SEQ ID NO: 8 is EGX7ARYX8GMDV, where X7 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, and X8 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; The amino acid sequence of SEQ ID NO: 14 is RASQSINSX. 11 LN, X 11 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and / or The amino acid sequence of SEQ ID NO: 18 is X 13 AX 14 NLX 15 S, X 13 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 14 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 15 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0050] This disclosure provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 3, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 9, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 15, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 19, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0051] In some embodiments, the amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, where X4 = S or G, X5 = N or Y, and X6 = N or Y.
[0052] In some embodiments, the amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 GMDV, X9 = A or R, X 10 =Y or F.
[0053] In some embodiments, the amino acid sequence of SEQ ID NO: 15 is RASQSINSX. 12 LN, X 12 =Y or F.
[0054] In some embodiments, the amino acid sequence of SEQ ID NO: 19 is X. 16 AX 17 NLX 18 S, X 16 =A or D, X 17 =S or T, X 18 =Q or R.
[0055] In some embodiments, the amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, where X4 = S or G, X5 = N or Y, and X6 = N or Y; The amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 GMDV, X9 = A or R, X 10 =Y or F; The amino acid sequence of SEQ ID NO: 15 is RASQSINSX. 12 LN, X 12 =Y or F; and / or The amino acid sequence of SEQ ID NO: 19 is X 16 AX 17 NLX 18 S, X16 =A or D, X 17 =S or T, X 18 =Q or R.
[0056] In some embodiments, the amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, X4=S, X5=N, X6=N; X4=S, X5=Y, X6=N; X4=G, X5=N, X6=N; X4=G, X5=Y, X6=N; X4=S, X5=N, X6=Y; X4=S, X5=Y, X6=Y; X4=G, X5=N, X6=Y; or, X4=G, X5=Y, X6=Y.
[0057] In some embodiments, the amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 GMDV, X9=A, X 10 =Y;X9=A,X 10 =F;X9=R,X 10 =Y; or, X9=R, X 10 =F.
[0058] In some embodiments, the amino acid sequence of SEQ ID NO: 15 is RASQSINSX. 12 LN, X 12 =Y or F.
[0059] In some embodiments, the amino acid sequence of SEQ ID NO: 19 is X. 16 AX 17 NLX 18 S, X 16 =A,X 17 =S,X 18 =Q;X 16 =A,X 17 =S,X 18 =R;X 16 =D, X 17 =S,X 18 =Q;X 16 =D, X 17 =S,X 18 =R;X 16 =A,X 17 =T,X 18 =Q;X 16 =A,X 17 =T,X 18 =R;X 16 =D, X 17 =T,X 18 =Q; or, X 16=D, X 17 =T,X 18 =R.
[0060] In some embodiments, the amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, X4=S, X5=N, X6=N; X4=S, X5=Y, X6=N; X4=G, X5=N, X6=N; X4=G, X5=Y, X6=N; X4=S, X5=N, X6=Y; X4=S, X5=Y, X6=Y; X4=G, X5=N, X6=Y; or, X4=G, X5=Y, X6=Y; The amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 GMDV, X9=A, X 10 =Y;X9=A,X 10 =F;X9=R,X 10 =Y; or, X9=R, X 10 =F; The amino acid sequence of SEQ ID NO: 15 is RASQSINSX. 12 LN, X 12 =Y or F; and / or The amino acid sequence of SEQ ID NO: 19 is X 16 AX 17 NLX 18 S, X 16 =A,X 17 =S,X 18 =Q;X 16 =A,X 17 =S,X 18 =R;X 16 =D, X 17 =S,X 18 =Q;X 16 =D, X 17 =S,X 18 =R;X 16 =A,X 17 =T,X 18 =Q;X 16 =A,X 17 =T,X 18 =R;X 16 =D, X 17 =T,X 18 =Q; or, X 16 =D, X 17 =T,X 18 =R.
[0061] In some embodiments, the amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, and the amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 The amino acid sequence of GMDV, SEQ ID NO: 15 is RASQSINSX. 12 The amino acid sequence of LN, SEQ ID NO: 19 is X 16 AX 17 NLX 18 S,X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =D, X 17 =S,X 18 =Q; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =D, X 17 =S,X 18 =R; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X 16 =D, X 17 =T,X 18 =Q; X4=S, X5=N, X6=N, X9=A, X 10 =Y,X 12 =Y,X16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18=Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12=F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18=R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12=F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18=Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12=Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18=R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12=Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18=Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12=Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18=R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12=F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18=Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12=F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18=R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=A,X 10 =F,X 12=F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18=Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12=Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18=R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12=Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18=Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12=F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18=R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12=F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18=Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12=F,X 16 =D,X 17 =T,X 18 =Q;X4=S,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18=R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12=Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18=Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12=Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18=R;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12=Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18=Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12=F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18=R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12=F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18=Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12=Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18=R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=N,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12=Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18=Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12=Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18=R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12=F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18=Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12=F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=N,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18=R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =Y,X 12=F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18=Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=A,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12=Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =A,X 17 =T,X 18=R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =Y,X 12 =F,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12=Y,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =Y,X 16 =D,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =A,X 17 =T,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =Q;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =S,X 18 =R;X4=G,X5=Y,X6=Y,X9=R,X 10 =F,X 12 =F,X 16 =D,X 17 =T,X 18=Q; or, X4=G, X5=Y, X6=Y, X9=R, X 10 =F,X 12 =F,X 16 =D, X 17 =T,X 18 =R.
[0062] This disclosure provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1; HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, 5, 6 or 7; HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, 11, 12 or 13; LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16 or 17; LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, 21, 22 or 23; and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0063] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0064] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0065] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0066] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0067] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0068] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0069] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0070] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0071] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0072] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0073] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0074] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:6, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0075] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0076] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0077] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0078] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0079] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0080] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0081] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0082] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0083] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0084] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0085] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0086] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0087] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0088] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0089] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0090] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0091] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0092] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0093] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0094] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0095] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0096] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0097] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0098] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0099] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:11, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0100] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:7, HCDR3 containing the amino acid sequence shown in SEQ ID NO:12, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0101] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0102] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0103] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0104] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0105] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0106] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:16, LCDR2 containing the amino acid sequence shown in SEQ ID NO:23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0107] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:4, HCDR3 containing the amino acid sequence shown in SEQ ID NO:13, LCDR1 containing the amino acid sequence shown in SEQ ID NO:17, LCDR2 containing the amino acid sequence shown in SEQ ID NO:21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:24.
[0108] This disclosure also provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 25, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 39. The CDRs are defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0109] In some embodiments, the amino acid sequence of SEQ ID NO: 25 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 19 YDGRX 20 KX21 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 22 ARYX 23 GMDVWGQGTTVTVSS, X 19 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 20 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 21 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 22 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 23 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0110] In some embodiments, the amino acid sequence of SEQ ID NO: 39 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 29 LNWYQQKPGKDPKLLIYX 30 AX 31 NLX 32 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 29 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 30 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 31 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 32 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0111] In some embodiments, the amino acid sequence of SEQ ID NO: 25 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 19 YDGRX 20 KX 21 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 22ARYX 23 GMDVWGQGTTVTVSS, X 19 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 20 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 21 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 22 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 23 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and / or In some embodiments, the amino acid sequence of SEQ ID NO: 39 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 29 LNWYQQKPGKDPKLLIYX 30 AX 31 NLX 32 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 29 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 30 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 31 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 32 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0112] This disclosure also provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 26, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 40. The CDRs are defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0113] In some embodiments, the amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28 GMDVWGQGTTVTVSS, X 24 =S or G, X 25 =N or Y, X 26 =N or Y, X 27 =A or R, X 28 =Y or F.
[0114] In some embodiments, the amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 33 =Y or F, X 34 =A or D, X 35 =S or T, X 36 =Q or R.
[0115] In some embodiments, the amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28 GMDVWGQGTTVTVSS, X 24 =S or G, X 25 =N or Y, X 26 =N or Y, X 27 =A or R, X 28 =Y or F; and / or The amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 33 =Y or F, X 34 =A or D, X 35 =S or T, X 36 =Q or R.
[0116] In some embodiments, the amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28 GMDVWGQGTTVTVSS, X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X28 =F;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y;X 24 =G,X 25 =N,X 26 =N,X27 =A,X 28 =F;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y;X 24 =G,X 25 =Y,X26 =Y,X 27 =A,X 28 =F;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y; or, X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F.
[0117] In some embodiments, the amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 33 =Y,X 34 =D, X 35 =S,X 36 =Q;X 33 =Y,X 34 =D, X 35 =S,X 36 =R;X 33 =Y,X 34 =D, X 35 =T,X 36 =Q;X 33 =Y,X 34 =D, X 35 =T,X 36 =R;X 33 =F,X34 =A,X 35 =S,X 36 =Q;X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 33 =F,X 34 =D, X 35 =S,X 36 =Q;X 33 =F,X 34 =D, X 35 =S,X 36 =R;X 33 =F,X 34 =D, X 35 =T,X 36 =Q; or, X 33 =F,X 34 =D, X 35 =T,X 36 =R.
[0118] In some embodiments, the amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28 GMDVWGQGTTVTVSS, X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F;X 24 =S,X 25 =N,X 26 =N,X 27=R,X 28 =Y;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F;X 24 =S,X 25 =Y,X 26=Y,X 27 =R,X 28 =Y;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F;X 24 =G,X 25=Y, X 26 =N, X 27 =R, X 28 =Y; X 24 =G, X 25 =Y, X 26 =N, X 27 =R, X 28 =F; X 24 =G, X 25 =Y, X 26 =Y, X 27 =A, X 28 =Y; X 24 =G, X 25 =Y, X 26 =Y, X 27 =A, X 28 =F; X 24 =G, X 25 =Y, X 26 =Y, X 27 =R, X 28 =Y; alternatively, X 24 =G, X 25 =Y, X 26 =Y, X 27 =R, X 28 =F; and / or The amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK, X 33 =Y, X 34 =A, X 35 =S, X 36 =Q; X 33 =Y, X 34 =A, X 35 =S, X 36 =R; X 33 =Y, X 34 =A, X 35 =T, X 36 =Q; X 33 =Y, X 34 =A, X 35 =T, X 36 =R; X 33 =Y, X 34 =D, X 35=S,X 36 =Q;X 33 =Y,X 34 =D, X 35 =S,X 36 =R;X 33 =Y,X 34 =D, X 35 =T,X 36 =Q;X 33 =Y,X 34 =D, X 35 =T,X 36 =R;X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 33 =F,X 34 =D, X 35 =S,X 36 =Q;X 33 =F,X 34 =D, X 35 =S,X 36 =R;X 33 =F,X 34 =D, X 35 =T,X 36 =Q; or, X 33 =F,X 34 =D, X 35 =T,X 36 =R.
[0119] In some embodiments, the amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28GMDVWGQGTTVTVSS, the amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK, X 24 =S, X 25 =N, X 26 =N, X 27 =A, X 28 =Y, X 33 =Y, X 34 =A, X 35 =S, X 36 =Q; X 24 =S, X 25 =N, X 26 =N, X 27 =A, X 28 =Y, X 33 =Y, X 34 =A, X 35 =S, X 36 =R; X 24 =S, X 25 =N, X 26 =N, X 27 =A, X 28 =Y, X 33 =Y, X 34 =A, X 35 =T, X 36 =Q; X 24 =S, X 25 =N, X 26 =N, X 27 =A, X 28 =Y, X 33 =Y, X 34 =A, X 35 =T, X 36 =R; X 24 =S, X 25 =N, X 26 =N, X 27 =A, X 28 =Y, X 33 =Y, X 34 =D, X 35 =S, X 36 =Q; X 24 =S, X 25 =N, X26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =A,X28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =S,X 25 =Y,X 26 =Y,X27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =S,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X25 =N,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =N,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =N,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =A,X 28 =F,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =A,X35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =Y,X 33 =F,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X28 =F,X 33 =Y,X 34 =D,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =S,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =A,X 35 =T,X 36 =R;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =Q;X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D,X 35 =S,X 36 =R;X24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D, X 35 =T,X 36 =Q; or, X 24 =G,X 25 =Y,X 26 =Y,X 27 =R,X 28 =F,X 33 =F,X 34 =D, X 35 =T,X 36 =R.
[0120] This disclosure also provides an anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41, 42, 43, 44, 45, or 46. The CDRs are defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0121] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0122] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0123] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0124] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0125] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0126] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0127] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0128] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0129] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0130] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0131] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0132] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0133] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0134] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0135] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0136] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41.
[0137] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0138] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0139] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0140] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0141] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0142] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0143] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0144] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43.
[0145] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0146] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0147] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0148] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0149] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0150] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0151] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0152] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0153] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0154] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0155] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0156] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0157] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0158] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0159] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46.
[0160] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0161] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0162] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42.
[0163] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46.
[0164] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44.
[0165] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45.
[0166] In some implementations, the CDR is defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0167] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38.
[0168] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41, 42, 43, 44, 45, or 46.
[0169] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 41, 42, 43, 44, 45, or 46.
[0170] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0171] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0172] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0173] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 30. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0174] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0175] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0176] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0177] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 30. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0178] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0179] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0180] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0181] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 30. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0182] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0183] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0184] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0185] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 41. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0186] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0187] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 13, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0188] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0189] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0190] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0191] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0192] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0193] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 43. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0194] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0195] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0196] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0197] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 35. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0198] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0199] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0200] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0201] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 35. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0202] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 36. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0203] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0204] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 36. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0205] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0206] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 36. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0207] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0208] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 46. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 46. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0209] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0210] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0211] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 42. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0212] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 46. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 46. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0213] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 44. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24.
[0214] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 45. Furthermore, in some such embodiments, the anti-ActRII antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 13, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 17, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0215] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0216] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0217] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0218] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0219] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0220] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0221] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0222] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0223] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0224] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0225] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0226] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0227] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0228] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0229] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0230] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:41.
[0231] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0232] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0233] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0234] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0235] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0236] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0237] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0238] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:43.
[0239] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0240] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0241] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0242] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:35, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0243] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0244] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0245] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0246] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:35, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0247] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0248] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0249] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0250] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0251] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0252] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0253] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:46.
[0254] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0255] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0256] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:42.
[0257] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:46.
[0258] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:44.
[0259] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:45.
[0260] In this disclosure, the antigen-binding fragment is a Fab fragment, an F(ab')2 fragment, an Fd fragment, an Fv fragment, a separated CDR region, or a scFv. In this disclosure, the anti-ActRII antibody or its antigen-binding fragment is fully human.
[0261] In some embodiments, the anti-ActRII antibody or its antigen-binding fragment of the present disclosure may further comprise a constant region of an immunoglobulin, or a fragment, analog, variant, or derivative of said constant region. In some embodiments, the constant region comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is derived from the heavy chain of human immunoglobulins, such as IgG1, IgG2, IgG3, IgG4, or other classes of immunoglobulins. In some embodiments, the light chain constant region is derived from the light chain of human immunoglobulins, such as the κ or λ light chain of human immunoglobulins. In some embodiments, the anti-ActRII antibody is an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the constant region may comprise any modification of the present disclosure or known in the art, such as the insertion, deletion, substitution, or chemical modification of amino acids. In some embodiments, the C-terminal lysine of the heavy chain constant region may be present or absent. In some embodiments, the heavy chain constant region comprises a mutation that prolongs the antibody's half-life. In some embodiments, the heavy chain constant region contains YTE mutations (M252Y, S254T, and T256E according to EU designations). In some embodiments, the constant region contains mutations that alter effector functions (such as ADCC and / or CDC). In some embodiments, the heavy chain constant region contains LALA mutations (L234A and L235A according to EU designations). In some embodiments, the heavy chain constant region contains P329A or P329G mutations (according to EU designations). In some embodiments, the heavy chain constant region contains LALAPA mutations (L234A, L235A, and P329A according to EU designations). In some embodiments, the heavy chain constant region contains LALAPG mutations (L234A, L235A, and P329G according to EU designations). In some embodiments, any amino acid residue in the constant region can be substituted with any allotype amino acid residue.
[0262] In some specific embodiments, the anti-ActRII antibody comprises a heavy chain whose amino acid sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, or 75.
[0263] In some specific embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77, 79, 81, 83, 85, or 100%.
[0264] In some specific embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, 49, 51, 53, 55, 57, 59, 61, 63, 88%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77, 79, 81, 83, 85, or 87, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77, 79, 81, 83, 85, or 87.
[0265] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 47. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 77. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0266] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 77. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0267] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 51. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 77. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0268] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 53. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 77. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 77. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0269] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 47. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 79. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 79. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0270] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 79. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 79. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0271] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 51. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 79. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 79. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0272] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 53. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 79. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 79. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0273] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 47. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 81. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 81. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 4, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0274] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 49. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 81. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 81. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0275] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 51. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 81. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 81. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0276] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 53. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 81. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 81. Furthermore, in some such embodiments, the anti-ActRII antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 24.
[0277] In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 55. In some embodiments, the anti-ActRII antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 77. In some embodiments, the anti-ActRII antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence...
Claims
1. An anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 8, LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 14, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 18, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:
24. in, The amino acid sequence of SEQ ID NO: 2 is VIX1YDGRX2KX3YADSVKG, where X1 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; X2 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and X3 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. The amino acid sequence of SEQ ID NO: 8 is EGX7ARYX8GMDV, where X7 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V, and X8 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. The amino acid sequence of SEQ ID NO: 14 is RASQSINSX 11 LN, X 11 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V, The amino acid sequence of SEQ ID NO: 18 is X 13 AX 14 NLX 15 S, X 13 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V, X 14 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V, X 15 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V.
2. The anti-ActRII antibody or its antigen-binding fragment according to claim 1, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 3, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 9, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 15, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 19, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
24. The amino acid sequence of SEQ ID NO: 3 is VIX4YDGRX5KX6YADSVKG, where X4 = S or G, X5 = N or Y, and X6 = N or Y. The amino acid sequence of SEQ ID NO: 9 is EGX9ARYX. 10 GMDV, X9 = A or R, X 10 =Y or F, The amino acid sequence of SEQ ID NO: 15 is RASQSINSX. 12 LN, X 12 =Y or F, The amino acid sequence of SEQ ID NO: 19 is X 16 AX 17 NLX 18 S, X 16 =A or D, X 17 =S or T, X 18 =Q or R.
3. The anti-ActRII antibody or its antigen-binding fragment according to claim 1 or 2, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, 5, 6 or 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, 11, 12 or 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16 or 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, 21, 22 or 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
24.
4. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-3, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: (1) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (2) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (3) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (4) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (5) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (6) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (7) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (8) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (9) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (10) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 10, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (11) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (12) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 6, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (13) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (14) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (15) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (16) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 20, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (17) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (18) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (19) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (20) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (21) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (22) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (23) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (24) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 22, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (25) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (26) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (27) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (28) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (29) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (30) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (31) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (32) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (33) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (34) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (35) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (36) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (37) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 11, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (38) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 7, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 12, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (39) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (40) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (41) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 5, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (42) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (43) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; (44) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 16, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 23, and LCDR3 containing the amino acid sequence shown in SEQ ID NO: 24; or (45) HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, HCDR2 containing the amino acid sequence shown in SEQ ID NO: 4, HCDR3 containing the amino acid sequence shown in SEQ ID NO: 13, LCDR1 containing the amino acid sequence shown in SEQ ID NO: 17, LCDR2 containing the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
24.
5. An anti-ActRII antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 25, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 39, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG. in, The amino acid sequence of SEQ ID NO: 25 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 19 YDGRX 20 KX 21 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 22 ARYX 23 GMDVWGQGTTVTVSS, X 19 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 20 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 21 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 22 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 23 = A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, The amino acid sequence of SEQ ID NO: 39 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 29 LNWYQQKPGKDPKLLIYX 30 AX 31 NLX 32 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 29 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 30 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 31 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V, X 32 =A, R, N, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.
6. The anti-ActRII antibody or its antigen-binding fragment according to claim 5, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 26, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 40, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG. The amino acid sequence of SEQ ID NO: 26 is QVQLVESGGGVVQPGRSLRLSCVASGFTFRSYVMYWVRQAPGKGLEWVAVIX 24 YDGRX 25 KX 26 YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGX 27 ARYX 28 GMDVWGQGTTVTVSS, X 24 =S or G, X 25 =N or Y, X 26 =N or Y, X 27 =A or R, X 28 =Y or F, The amino acid sequence of SEQ ID NO: 40 is DIQMTQSPSSLSASVGDRVTTTCRASQSINSX 33 LNWYQQKPGKDPKLLIYX 34 AX 35 NLX 36 SGVPSRFGGSGSGTDFTLTINNLQPEDFAIYFCQQSYSPPITFGQGTRLEIK,X 33 =Y or F, X 34 =A or D, X 35 =S or T, X 36 =Q or R.
7. The anti-ActRII antibody or its antigen-binding fragment according to claim 5 or 6, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41, 42, 43, 44, 45, or 46, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
8. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 5-7, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 28, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 29, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 30, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (16) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 41; (17) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (18) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (19) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (20) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (21) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (22) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (23) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (24) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 43; (25) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (26) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (27) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (28) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (29) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (30) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 34, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (31) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 33, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (32) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 35, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (33) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (34) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (35) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (36) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (37) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (38) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (39) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46; (40) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; (41) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 32, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; (42) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 42; (43) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 46; (44) The amino acid sequences of HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 44; or (45) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 45; The CDR is defined according to Kabat, IMGT, Chothia, Contact, AbM and / or CCG.
9. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-8, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38.
10. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-9, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 41, 42, 43, 44, 45, or 46.
11. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-10, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: (1) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (2) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (3) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (4) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (5) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (6) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (7) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (8) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (9) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (10) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (11) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (12) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (13) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (14) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (15) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (16) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 41; (17) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (18) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (19) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (20) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (21) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (22) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (23) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (24) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 43; (25) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (26) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (27) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (28) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (29) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (30) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (31) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (32) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (33) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (34) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (35) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (36) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (37) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (38) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (39) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 46; (40) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; (41) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 45; (42) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 42; (43) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 46; (44) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 44; or (45) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence shown in SEQ ID NO:
45.
12. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-11, wherein, The anti-ActRII antibody or its antigen-binding fragment comprises: (1) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (2) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (3) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (4) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (5) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (6) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (7) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (8) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (9) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (10) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 28, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (11) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 29, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (12) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 30, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (13) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (14) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (15) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (16) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41; (17) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (18) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (19) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (20) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (21) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (22) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (23) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (24) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; (25) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (26) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (27) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (28) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (29) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (30) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 34, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (31) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 33, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (32) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 35, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (33) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (34) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (35) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (36) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (37) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (38) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (39) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 46; (40) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; (41) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 32, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 45; (42) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; (43) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 46; (44) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 44; or (45) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 38, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:
45.
13. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-12, wherein, The antigen-binding fragment is a Fab fragment, an F(ab')2 fragment, an Fd fragment, an Fv fragment, a separated CDR region, or a scFv.
14. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-13, wherein, The anti-ActRII antibody is an isotype of IgG1, IgG2, IgG3 or IgG4.
15. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-14, wherein, The anti-ActRII antibody comprises a heavy chain whose amino acid sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, or 75.
16. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-15, wherein, The anti-ActRII antibody comprises a light chain whose amino acid sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 77, 79, 81, 83, 85, or 100%.
17. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-16, wherein, The anti-ActRII antibody comprises: (1) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (2) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (3) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (4) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (5) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (6) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (7) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (8) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (9) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 47, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (10) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 49, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (11) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 51, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (12) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 53, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (13) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (14) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (15) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 63, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (16) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 77; (17) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (18) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 57, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (19) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (20) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 61, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (21) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 63, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (22) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (23) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (24) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (25) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 63, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (26) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 81; (27) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (28) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (29) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 63, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (30) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 67, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (31) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 55, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (32) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (33) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 63, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (34) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 67, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (35) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 69, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (36) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 71, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (37) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 69, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (38) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 71, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (39) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 69, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (40) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 71, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (41) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 87; (42) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (43) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 85; (44) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 73, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 79; (45) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 73, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 87; (46) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 73, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 83; (47) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 75, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 83; or (48) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 73, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:
85.
18. An anti-ActRII antibody or an antigen-binding fragment thereof, wherein, The anti-ActRII antibody comprises: (1) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 47, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (2) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 49, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (3) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 51, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (4) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 53, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (5) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 47, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (6) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 49, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (7) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 51, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (8) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 53, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (9) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 47, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (10) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 49, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (11) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 51, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (12) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 53, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (13) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 55, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (14) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (15) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (16) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 65, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (17) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 55, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (18) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 57, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (19) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (20) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 61, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (21) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (22) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 65, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (23) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 55, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (24) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (25) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (26) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 65, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (27) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 55, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (28) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 65, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (29) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (30) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 67, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (31) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 55, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (32) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 65, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (33) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (34) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 67, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (35) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 69, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (36) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 71, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (37) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 69, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (38) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 71, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (39) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 69, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (40) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 71, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (41) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 87; (42) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (43) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 59, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 85; (44) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 73, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 79; (45) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 73, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 87; (46) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 73, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; (47) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 75, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83; or (48) A heavy chain comprising the amino acid sequence shown in SEQ ID NO: 73 and a light chain comprising the amino acid sequence shown in SEQ ID NO:
85.
19. The anti-ActRII antibody or its antigen-binding fragment according to any one of claims 1-18, wherein, The anti-ActRII antibody or its antigen-binding fragment has one or more of the following properties: (1) Combined human ActRIIA; preferably, measured by surface plasmon resonance technology, with a KD of 5.00E-07 M or less, 1.00E-07 M or less, or 5.00E-08 M or less combined human ActRIIA; (2) Human ActRIIB; preferably, measured by surface plasmon resonance technology, with a KD of 1.00E-08 M or less, 8.00E-09 M or less, or 6.00E-09 M or less; (3) Competing with ActivinA, GDF8 and / or GDF11 to bind to human ActRIIA and / or ActRIIB; (4) Promotes muscle formation; (5) Reduce fat formation; (6) Induces tumor growth and regression in vivo; and (7) Delay the growth of tumors in the body.
20. An isolated nucleic acid comprising a nucleotide sequence encoding an anti-ActRII antibody or an antigen-binding fragment thereof as described in any one of claims 1-19.
21. A vector comprising the nucleic acid of claim 20.
22. A host cell comprising the nucleic acid of claim 20 or the vector of claim 21.
23. A method for preparing an anti-ActRII antibody or an antigen-binding fragment thereof according to any one of claims 1-19, comprising culturing the host cell of claim 22 to express the anti-ActRII antibody or an antigen-binding fragment thereof, and isolating and purifying the anti-ActRII antibody or an antigen-binding fragment thereof in the system.
24. A fusion protein comprising the anti-ActRII antibody or its antigen-binding fragment as described in any one of claims 1-19.
25. An antibody-drug conjugate comprising the anti-ActRII antibody or its antigen-binding fragment as described in any one of claims 1-19.
26. A chimeric antigen receptor comprising the anti-ActRII antibody or its antigen-binding fragment as described in any one of claims 1-19.
27. An engineered immune effector cell comprising the chimeric antigen receptor of claim 26.
28. A pharmaceutical composition comprising an anti-ActRII antibody or an antigen-binding fragment thereof according to any one of claims 1-19, a fusion protein according to claim 24, an antibody-drug conjugate according to claim 25, or an engineered immune effector cell according to claim 27; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
29. Use of the anti-ActRII antibody or antigen-binding fragment thereof according to any one of claims 1-19, the fusion protein according to claim 24, the antibody-drug conjugate according to claim 25, the engineered immune effector cell according to claim 27, or the pharmaceutical composition according to claim 28 in the preparation of a medicament for treating diseases related to ActRII expression or ActRII signaling.
30. The use according to claim 29, wherein, The diseases mentioned are musculoskeletal system diseases, endocrine and metabolic system diseases, immune system diseases, blood diseases, cardiovascular system diseases, fibrotic diseases and / or tumors.
31. The use according to claim 29 or 30, wherein, The diseases mentioned are myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis, and / or tumors.
32. A method of treating a disease associated with ActRII expression or ActRII signaling, comprising administering to a subject an anti-ActRII antibody or an antigen-binding fragment thereof as described in any one of claims 1-19, a fusion protein as described in claim 24, an antibody-drug conjugate as described in claim 25, engineered immune effector cells as described in claim 27, or a pharmaceutical composition as described in claim 28.
33. The method according to claim 32, wherein, The method includes further administering one or more additional therapeutic agents to the subject; preferably, the additional therapeutic agent is a GLP-1 receptor agonist; more preferably, the additional therapeutic agent is semaglutide.
34. The method according to claim 32 or 33, wherein, The diseases mentioned are musculoskeletal system diseases, endocrine and metabolic system diseases, immune system diseases, blood diseases, cardiovascular system diseases, fibrotic diseases and / or tumors.
35. The method according to any one of claims 32-34, wherein, The diseases mentioned are myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis, and / or tumors.
36. A kit comprising the anti-ActRII antibody or its antigen-binding fragment as described in any one of claims 1-19, the fusion protein of claim 24, the antibody-drug conjugate of claim 25, the engineered immune effector cells of claim 27, or the pharmaceutical composition of claim 28.
Citation Information
Patent Citations
Anti-ACVR2a antibodies and uses thereof
WO2023030503A1
